Publications by authors named "Jayde Powell"
Article Synopsis
- Two monoclonal antibodies, aducanumab and lecanemab, have gained accelerated approval from the US FDA for treating early Alzheimer's disease patients with confirmed β-amyloid pathology.
- Lecanemab has received full approval, and other similar antibodies are expected to receive positive reviews due to their ability to significantly reduce brain Aβ levels.
- These mAbs can slow cognitive decline by approximately 30%, marking a meaningful advancement in Alzheimer's treatment, though further improvements in efficacy and safety are necessary.
